{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:16:45Z","timestamp":1747801005700,"version":"3.41.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Topiramate has shown efficacy in reducing alcohol consumption and is increasingly used off-label for individuals with harmful alcohol use. However, findings regarding the moderating effect of the <jats:italic>GRIK1<\/jats:italic> rs2832407 single nucleotide polymorphism (SNP) on treatment outcomes remain inconsistent, highlighting the need for a review of the current evidence. We evaluated whether the <jats:italic>GRIK1<\/jats:italic> rs2832407 SNP moderates the efficacy and safety of topiramate treatment for alcohol use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We searched multiple databases including MEDLINE, Cochrane Library, ClinicalTrials.gov, and the International Clinical Trials Registry Platform up to December 1, 2024. Randomized controlled trials (RCTs) comparing treatment outcomes of topiramate in patients with alcohol use who were homozygous for the C allele at rs2832407 with those carrying one or more A alleles at rs2832407 were included. Primary outcomes were heavy drinking days (HDDs) and percentage of days abstinent (PDA), and the secondary outcome was side effects. Each outcome was evaluated using version 2 of the Cochrane Risk of Bias tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our analysis included four RCTs. Among three studies evaluating HDDs, only one study demonstrated genotype effects, demonstrating a reduction in HDDs among CC carriers. Of two studies examining PDA, only one revealed genotype effects, indicating an increase in PDA. Side effects were evaluated in two studies, both of which assessed the severity of side effects, but with conflicting results regarding the effect of genotype.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This systematic review highlights the current lack of sufficient evidence to confirm the pharmacogenetic effect of the <jats:italic>GRIK1<\/jats:italic> rs2832407 SNP on the efficacy or safety of topiramate treatment in individuals with harmful alcohol use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>This research was prospectively registered with the Open Science Framework (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/osf.io\/z2awu\/\" ext-link-type=\"uri\">https:\/\/osf.io\/z2awu\/<\/jats:ext-link>).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00449-y","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:45:04Z","timestamp":1747741504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GRIK1 genotype and effect of topiramate for alcohol use: a systematic review"],"prefix":"10.1186","volume":"11","author":[{"given":"Kazumasa","family":"Kotake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Matsunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"449_CR1","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3350\/cmh.2020.0160","volume":"26","author":"SH Park","year":"2020","unstructured":"Park SH, Kim DJ. Global and regional impacts of alcohol use on public health: emphasis on alcohol policies. Clin Mol Hepatol. 2020;26:652\u201361.","journal-title":"Clin Mol Hepatol"},{"key":"449_CR2","unstructured":"Alcohol. [cited 2024 Feb 7]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol"},{"key":"449_CR3","first-page":"CD013350","volume":"5","author":"MC Greene","year":"2023","unstructured":"Greene MC, Kane J, Alto M, Giusto A, Lovero K, Stockton M, et al. Psychosocial and Pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries. Cochrane Database Syst Rev. 2023;5:CD013350.","journal-title":"Cochrane Database Syst Rev"},{"key":"449_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","volume":"3","author":"GF Koob","year":"2016","unstructured":"Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760\u201373.","journal-title":"Lancet Psychiatry"},{"key":"449_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","volume":"45","author":"LAPD Ray","year":"2019","unstructured":"Ray LAPD, Bujarski S, PhD, Grodin E, PhD, Hartwell E, PhD, Green RMA, Venegas ABS, et al. State-of-the-art behavioral and Pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45:124\u201340.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"449_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jcbfm.2010.191","volume":"31","author":"M Lauritzen","year":"2011","unstructured":"Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab. 2011;31:17\u201335.","journal-title":"J Cereb Blood Flow Metab"},{"key":"449_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4137\/JCNSD.S4365","volume":"3","author":"GC Minton","year":"2011","unstructured":"Minton GC, Miller AD, Bookstaver PB, Love BL. Topiramate: safety and efficacy of its use in the prevention and treatment of migraine. J Cent Nerv Syst Dis. 2011;3:155\u201368.","journal-title":"J Cent Nerv Syst Dis"},{"key":"449_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1517\/14740338.6.5.547","volume":"6","author":"D Vega","year":"2007","unstructured":"Vega D, Maalouf NM, Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf. 2007;6:547\u201357.","journal-title":"Expert Opin Drug Saf"},{"key":"449_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/00007691-200206000-00002","volume":"24","author":"M Contin","year":"2002","unstructured":"Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2002;24:332\u20137.","journal-title":"Ther Drug Monit"},{"key":"449_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38:1481\u20138.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1176\/appi.ajp.20230666","volume":"181","author":"KC Morley","year":"2024","unstructured":"Morley KC, Kranzler HR, Luquin N, Jamshidi N, Adams C, Montebello M, et al. Topiramate versus Naltrexone for alcohol use disorder: A genotype-stratified double-blind randomized controlled trial. Am J Psychiatry. 2024;181:403\u201311.","journal-title":"Am J Psychiatry"},{"key":"449_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1037\/a0015700","volume":"17","author":"LA Ray","year":"2009","unstructured":"Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, et al. A preliminary Pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17:122\u20139.","journal-title":"Exp Clin Psychopharmacol"},{"key":"449_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.pmbts.2015.10.018","volume":"137","author":"RL Bell","year":"2016","unstructured":"Bell RL, Hauser SR, McClintick J, Rahman S, Edenberg HJ, Szumlinski KK, et al. Ethanol-associated changes in glutamate reward neurocircuitry: A minireview of clinical and preclinical genetic findings. Prog Mol Biol Transl Sci. 2016;137:41\u201385.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"449_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1530-0277.2009.00913.x","volume":"33","author":"HR Kranzler","year":"2009","unstructured":"Kranzler HR, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, et al. Association of markers in the 3\u2019 region of the GluR5 Kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res. 2009;33:925\u201330.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171:445\u201352.","journal-title":"Am J Psychiatry"},{"key":"449_CR16","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1111\/acer.12578","volume":"38","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Wetherill R, Feinn R, Pond T, Gelernter J, Covault J. Posttreatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res. 2014;38:3017\u201323.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR17","doi-asserted-by":"publisher","first-page":"108762","DOI":"10.1016\/j.drugalcdep.2021.108762","volume":"225","author":"HR Kranzler","year":"2021","unstructured":"Kranzler HR, Hartwell EE, Feinn R, Pond T, Witkiewitz K, Gelernter J, et al. Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. Drug Alcohol Depend. 2021;225:108762.","journal-title":"Drug Alcohol Depend"},{"key":"449_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"449_CR19","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41386-020-00945-9","volume":"46","author":"HR Kranzler","year":"2021","unstructured":"Kranzler HR, Morris PE, Pond T, Crist RC, Kampman KM, Hartwell EE, et al. Prospective randomized Pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacology. 2021;46:1407\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"449_CR20","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. August. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated 2023). 2023."},{"key":"449_CR21","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. p. l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"449_CR22","first-page":"CD012557","volume":"1","author":"R Agabio","year":"2023","unstructured":"Agabio R, Saulle R, R\u00f6sner S, Minozzi S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2023;1:CD012557.","journal-title":"Cochrane Database Syst Rev"},{"key":"449_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neubiorev.2020.12.030","volume":"125","author":"R Agabio","year":"2021","unstructured":"Agabio R, Baldwin DS, Amaro H, Leggio L, Sinclair JMA. The influence of anxiety symptoms on clinical outcomes during Baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;125:296\u2013313.","journal-title":"Neurosci Biobehav Rev"},{"key":"449_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41397-021-00208-w","volume":"21","author":"S Turongkaravee","year":"2021","unstructured":"Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 2021;21:296\u2013307.","journal-title":"Pharmacogenomics J"},{"key":"449_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00228-023-03549-6","volume":"79","author":"S Wei","year":"2023","unstructured":"Wei S, Li X, Zhang Q, Wu H, Wu Y, Zhao Z, et al. Population pharmacokinetics of topiramate in Chinese children with epilepsy. Eur J Clin Pharmacol. 2023;79:1401\u201315.","journal-title":"Eur J Clin Pharmacol"},{"key":"449_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","volume":"16","author":"A Bahji","year":"2022","unstructured":"Bahji A, Bach P, Danilewitz M, Crockford D, Devoe DJ, El-Guebaly N, et al. Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis. J Addict Med. 2022;16:630\u20138.","journal-title":"J Addict Med"},{"key":"449_CR27","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/acer.14399","volume":"44","author":"R Lieberman","year":"2020","unstructured":"Lieberman R, Jensen KP, Clinton K, Levine ES, Kranzler HR, Covault J. Molecular correlates of topiramate and GRIK1 rs2832407 genotype in pluripotent stem cell-derived neural cultures. Alcohol Clin Exp Res. 2020;44:1561\u201370.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajmg.b.32379","volume":"168","author":"H Mbarek","year":"2015","unstructured":"Mbarek H, Milaneschi Y, Fedko IO, Hottenga J-J, de Moor MHM, Jansen R, et al. The genetics of alcohol dependence: twin and SNP-based heritability, and genome-wide association study based on AUDIT scores. Am J Med Genet B Neuropsychiatr Genet. 2015;168:739\u201348.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"449_CR29","doi-asserted-by":"crossref","unstructured":"Sanchez-Roige S, Fontanillas P, Elson SL, 23andMe Research Team, Gray JC, de Wit H et al. Genome-wide association study of alcohol use disorder identification test (AUDIT) scores in 20 328 research participants of European ancestry: GWAS of AUDIT. Addict Biol. 2019;24:121\u201331.","DOI":"10.1111\/adb.12574"},{"key":"449_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41467-019-09480-8","volume":"10","author":"HR Kranzler","year":"2019","unstructured":"Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC, Damrauer S, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:1499.","journal-title":"Nat Commun"},{"key":"449_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41593-020-0643-5","volume":"23","author":"H Zhou","year":"2020","unstructured":"Zhou H, Sealock JM, Sanchez-Roige S, Clarke T-K, Levey DF, Cheng Z, et al. Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nat Neurosci. 2020;23:809\u201318.","journal-title":"Nat Neurosci"},{"key":"449_CR32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2217\/pgs-2020-0079","volume":"21","author":"FW Lohoff","year":"2020","unstructured":"Lohoff FW. Pharmacotherapies and personalized medicine for alcohol use disorder: a review. Pharmacogenomics. 2020;21:1117\u201338.","journal-title":"Pharmacogenomics"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00449-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00449-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00449-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:45:09Z","timestamp":1747741509000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00449-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00449-y","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Systematic reviews use publicly accessible documents as evidence; therefore, they do not require ethics approval or consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Systematic reviews use publicly accessible documents as evidence; therefore, they do not require consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}